查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026737

前列腺癌診斷市場預測至2034年—按檢測類型、癌症類型、最終用戶和地區分類的全球分析

Prostate Cancer Diagnostics Market Forecasts to 2034 - Global Analysis By Test Type, Cancer Type, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球前列腺癌診斷市場規模將達到 111 億美元，並在預測期內以 8.23% 的複合年成長率成長，到 2034 年將達到 209 億美元。

為了早期發現和識別前列腺癌，前列腺癌的診斷採用多方面綜合方法。直腸指檢 (DRE)、經直腸超音波(TRUS)、磁振造影(MRI) 和攝護腺特異性抗原 (PSA) 血液檢測是重要的診斷技術。此外，PSA 檢測用於測量前列腺分泌的蛋白質含​​量，PSA 水平升高通常提示需要進一步檢查。直腸指檢有助於評估前列腺的大小和質地。

根據美國國家癌症研究所的數據，2019年美國新增前列腺癌病例超過174,650例。該機構的數據也顯示，2019年有超過31,620人死於攝護腺癌。

攝護腺癌發生率不斷上升

癌症篩檢技術的進步、人口老化以及生活方式的改變是全球前列腺癌發生率持續上升的主要原因。此外，人們對能夠早期準確識別和診斷前列腺癌的先進診斷工具的需求日益成長，加上篩檢計畫的普及和健康意識的提高，共同推動了市場成長。

昂貴的神經影像設備

醫療機構面臨著巨大的財務障礙，因為諸如磁振造影（MRI）等先進神經影像設備的成本極其高昂。尤其是在資源匱乏的環境中，購買和維護這些尖端設備所需的大量資金投入會限制患者獲得先進的診斷工具。此外，緩解這些限制需要創新的資金籌措策略和經濟實惠的替代方案。

神經影像技術的進步

隨著神經影像技術的不斷發展，市場預計將迎來顯著成長。腦磁圖（MEG）、正子斷層掃描（PET）和功能性磁振造影（fMRI）等診斷技術的進步，為提高靈敏度、解析度和診斷能力提供了契機。此外，對這些最尖端科技研發投入的持續成長，可望為精準、細緻的神經影像診斷創造新的機會。

來自替代診斷技術的威脅

傳統神經影像技術正受到新興替代診斷技術的威脅，例如穿戴式神經技術和腦脊髓液生物標記分析。此外，其現有的市場地位也受到非影像學方法的挑戰，因此，持續創新和差異化對於維持市場地位和確保市場佔有率至關重要。

新冠疫情的影響：

新冠疫情對神經影像市場產生了重大影響。這場全球健康危機的突然爆發，導致常規診斷測試、選擇性篩檢和非緊急就診等醫療服務受到干擾。由於社交距離措施的實施以及資源被分配到疫情應對工作中，神經影像的使用量有所下降。此外，供應鏈中斷和經濟的不確定性也影響了醫療機構的採購能力，延緩了尖端影像設備的購買。

在預測期內，前列腺腺癌細分市場預計將佔據最大的市場佔有率。

前列腺腺癌是市佔率最大的細分市場。大多數確診的前列腺癌都是前列腺腺癌，這也是最常見的前列腺癌類型。這種癌症起源於攝護腺的腺細胞，臨床表現和進行性都可能出現多種症狀。與前列腺腺癌高發生率相關的因素包括年齡、遺傳和荷爾蒙水平的影響。此外，如果沒有PSA檢測、直腸指檢（DRE）和先進的影像學檢查等診斷技術，前列腺腺癌的診斷和分型將十分困難。

在預測期內，診斷檢查室領域預計將呈現最高的複合年成長率。

市場中複合年成長率最高的細分領域是診斷檢查室。早期檢測的需求和疾病盛行率的上升推動了對診斷服務的需求，進而促進了診斷檢查室的成長。這些機構對於提供包括生物標記評估和癌症篩檢在內的各種診斷測試至關重要。此外，診斷技術的進步和對個人化醫療的重視也提升了診斷檢查室在醫療保健領域的重要性。

市佔率最大的地區：

北美在前列腺癌診斷市場佔最大佔有率。該地區前列腺癌發生率極高，早期便採用尖端診斷技術，並擁有完善的醫療保健基礎設施。此外，諸如PSA檢測等全面的篩檢項目，能夠實現可靠的早期發現和診斷。積極參與癌症研究、政府的大力支持以及公眾和專業人士的高度認知，進一步鞏固了北美在癌症診斷領域的領先地位。

複合年成長率最高的地區：

亞太地區前列腺癌診斷市場複合年成長率最高。前列腺癌發生率上升、早期檢測意識增強以及中國、印度和日本等國醫療衛生體系的發展是推動這一成長的主要因素。該地區人口老化和生活方式的改變加劇了前列腺癌發病率的上升，從而推動了對先進診斷技術的需求。此外，政府主導的各項措施、對醫療保健領域的投資以及與跨國診斷公司的合作，都在加速尖端診斷技術的應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球前列腺癌診斷市場：依檢測類型分類

  • 初步檢查
    • PSA檢測
    • 免費PSA檢測
    • 總PSA檢測
    • 其他初步檢查
  • 確認性試驗
    • PCA3 測試
    • 經直腸超音波檢查
    • 切片檢查
  • 免疫組織化學
  • 其他測試類型

第6章 全球前列腺癌診斷市場：依癌症類型分類

  • 良性攝護腺增生
  • 攝護腺腺癌
  • 小細胞癌
  • 其他癌症

第7章 全球前列腺癌診斷市場：依最終用戶分類

  • 醫院
  • 門診設施
  • 診斷檢查室
  • 癌症研究機構
  • 居家照護
  • 研究與製造
  • 其他最終用戶

第8章 全球前列腺癌診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Danaher Corporation
  • Abbott Laboratories
  • BioMerieux SA
  • F. Hoffman La Roche Ltd.
  • Bayer Aktiengesellschaft
  • Myriad Genetics Inc.
  • Genomic Health, Inc.
  • Agilent Technologies
  • Siemens Healthcare GmbH
  • Vyant Bio Inc.
  • Biocept Inc.
  • DiaSorin SpA
  • AstraZeneca Plc.
  • OPKO Health, Inc.
  • Becton Dickinson and Company
  • MDx Health
  • Foundation Medicine Inc.
  • Telo Genomics Corp（3D Signatures）
Product Code: SMRC24713

According to Stratistics MRC, the Global Prostate Cancer Diagnostics Market is accounted for $11.1 billion in 2026 and is expected to reach $20.9 billion by 2034 growing at a CAGR of 8.23% during the forecast period. In order to identify and describe prostate cancer in its early stages, prostate cancer diagnostics employ a multifaceted approach. Digital rectal examination (DRE), transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and the prostate-specific antigen (PSA) blood test are important diagnostic techniques. Moreover, the PSA test gauges the amount of a protein secreted by the prostate gland; high levels frequently signal the need for additional research. The evaluation of the prostate's size and texture is aided by a digital rectal examination.

According to the National Cancer Institute, in 2019, over 174,650 new cases of prostate cancer were diagnosed in the U.S. Additionally, data from the same source also suggests that over 31,620 deaths occurred in 2019 due to prostate cancer.

Market Dynamics:

Driver:

Growing prostate cancer incidence

Improved cancer detection techniques, aging populations, and altered lifestyles are the main causes of the prostate cancer incidence that has been rising steadily throughout the world. Furthermore, there is a growing need for sophisticated diagnostic tools that can precisely identify and characterize prostate cancer at its earliest stages, which is driving market growth as screening programs become more widely implemented and healthcare awareness increases.

Restraint:

Expensive neuroimaging equipment

Healthcare facilities face a major financial obstacle due to the prohibitive cost of sophisticated neuroimaging equipment, such as magnetic resonance imaging (MRI) machines. Access to advanced diagnostic tools may be restricted by the significant capital outlay necessary for purchasing and maintaining state-of-the-art machinery, especially in environments with limited resources. Additionally, it will take creative financing strategies and affordable substitutes to lessen this constraint.

Opportunity:

Technological developments in neuroimaging

The market is poised for substantial growth as long as neuroimaging technologies continue to progress. Advancements in diagnostic techniques like magnetoencephalography (MEG), positron emission tomography (PET), and functional magnetic resonance imaging (fMRI) present opportunities for increased sensitivity, resolution, and diagnostic power. Furthermore, putting money into research and development to incorporate these state-of-the-art technologies can lead to new opportunities for precise and thorough neuroimaging diagnosis.

Threat:

Threats from alternative diagnostic technologies

Traditional neuroimaging diagnostics are under threat from emerging alternative diagnostic technologies like wearable neurotechnology and cerebrospinal fluid biomarker analysis. Moreover, the market's established position is under threat from non-imaging modalities, so continued innovation and differentiation are necessary to stay relevant and hold onto market share.

Covid-19 Impact:

In the neuroimaging diagnostics market, the COVID-19 pandemic has had a significant effect. Healthcare services, such as regular diagnostic tests, elective screenings, and non-emergency medical visits, were disrupted by the abrupt start of the global health crisis. The application of social distancing measures and the allocation of resources to pandemic management led to a decrease in the use of neuroimaging diagnostics. Furthermore, healthcare facilities ability to make purchases was also impacted by supply chain disruptions and economic uncertainty, which caused delays in the purchase of cutting-edge imaging equipment.

The Prostatic Adenocarcinoma segment is expected to be the largest during the forecast period

The segment with the largest market share is prostate adenocarcinoma. The majority of cases of prostate cancer that are diagnosed are prostatic adenocarcinoma, which is the most common type of the disease. The prostate's glandular cells are the cancer's original site, and it can present in a variety of ways, both clinically and aggressively. Age, heredity, and hormonal influences are among the factors linked to the high incidence of prostatic adenocarcinoma. Moreover, prostatic adenocarcinoma is difficult to diagnose and characterize without the use of diagnostic techniques such as PSA testing, digital rectal examination (DRE), and advanced imaging technologies.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

In the market, the segment with the highest CAGR is diagnostic laboratories. The need for early detection and rising disease prevalence are driving up demand for diagnostic services, which in turn is fueling the growth of diagnostic laboratories. These establishments are crucial in offering an extensive array of diagnostic examinations, such as biomarker evaluations and cancer screenings. Additionally, diagnostic laboratories are becoming increasingly important in the healthcare environment as a result of improvements in diagnostic technologies and a focus on personalized medicine.

Region with largest share:

Concerning prostate cancer diagnostics, North America holds the largest market share. Prostate cancer is very common in the area; cutting-edge diagnostic technologies were adopted early; and the region has a strong healthcare infrastructure. Furthermore, a reliable means of early detection and diagnosis is through robust screening programs, like PSA testing. Further strengthening North America's position is proactive approaches to cancer research, robust government backing, and high levels of public and professional awareness.

Region with highest CAGR:

In terms of the market for prostate cancer diagnostics, the Asia-Pacific region has the highest CAGR. The rising incidence of prostate cancer, growing knowledge of early detection, and the development of the healthcare system in nations like China, India, and Japan are some of the reasons driving this growth. The need for sophisticated diagnostics is being driven by the region's aging population and changing lifestyles, which are factors in the rising incidence of prostate cancer. Additionally, the adoption of cutting-edge diagnostic technologies is being accelerated by government initiatives, healthcare investments, and partnerships with multinational diagnostic companies.

Key players in the market

Some of the key players in Prostate Cancer Diagnostics market include Danaher Corporation, Abbott Laboratories, BioMerieux SA, F. Hoffman La Roche Ltd., Bayer Aktiengesellschaft, Myriad Genetics Inc., Genomic Health, Inc., Agilent Technologies, Siemens Healthcare GmbH, Vyant Bio Inc., Biocept Inc., DiaSorin S.p.A, AstraZeneca Plc., OPKO Health, Inc., Becton Dickinson and Company, MDx Health, Foundation Medicine Inc. and Telo Genomics Corp (3D Signatures).

Key Developments:

In December 2023, Danaher Corp., a global life sciences and diagnostics provider based in Washington D.C., has completed its $5.7 billion acquisition of Abcam plc, a supplier of protein research tools for life sciences based in Cambridge, England. Abcam has become an indirect wholly owned subsidiary of Danaher. Danaher's Life Sciences businesses provide tools and technologies to support the advancement of pharmaceuticals and biopharmaceuticals.

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Test Types Covered:

  • Preliminary Tests
  • Confirmatory Tests
  • Immunohistochemistry
  • Other Test Types

Cancer Types Covered:

  • Benign Prostatic Hyperplasia
  • Prostatic Adenocarcinoma
  • Small Cell Carcinoma
  • Other Cancer Types

End Users Covered:

  • Hospitals
  • Outpatient Facilities
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Home Care
  • Research & Manufacturing
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Prostate Cancer Diagnostics Market, By Test Type

  • 5.1 Introduction
  • 5.2 Preliminary Tests
    • 5.2.1 PSA Tests
    • 5.2.2 Free PSA Test
    • 5.2.3 Total PSA Test
    • 5.2.4 Other Preliminary Tests
  • 5.3 Confirmatory Tests
    • 5.3.1 Pca3 Test
    • 5.3.2 Trans-Rectal Ultrasound
    • 5.3.3 Biopsy Test
  • 5.4 Immunohistochemistry
  • 5.5 Other Test Types

6 Global Prostate Cancer Diagnostics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Benign Prostatic Hyperplasia
  • 6.3 Prostatic Adenocarcinoma
  • 6.4 Small Cell Carcinoma
  • 6.5 Other Cancer Types

7 Global Prostate Cancer Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Outpatient Facilities
  • 7.4 Diagnostic Laboratories
  • 7.5 Cancer Research Institutes
  • 7.6 Home Care
  • 7.7 Research & Manufacturing
  • 7.8 Other End Users

8 Global Prostate Cancer Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Danaher Corporation
  • 10.2 Abbott Laboratories
  • 10.3 BioMerieux SA
  • 10.4 F. Hoffman La Roche Ltd.
  • 10.5 Bayer Aktiengesellschaft
  • 10.6 Myriad Genetics Inc.
  • 10.7 Genomic Health, Inc.
  • 10.8 Agilent Technologies
  • 10.9 Siemens Healthcare GmbH
  • 10.10 Vyant Bio Inc.
  • 10.11 Biocept Inc.
  • 10.12 DiaSorin S.p.A
  • 10.13 AstraZeneca Plc.
  • 10.14 OPKO Health, Inc.
  • 10.15 Becton Dickinson and Company
  • 10.16 MDx Health
  • 10.17 Foundation Medicine Inc.
  • 10.18 Telo Genomics Corp (3D Signatures)

List of Tables

  • Table 1 Global Prostate Cancer Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Prostate Cancer Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 3 Global Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2023-2034) ($MN)
  • Table 4 Global Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2023-2034) ($MN)
  • Table 5 Global Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2023-2034) ($MN)
  • Table 6 Global Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2023-2034) ($MN)
  • Table 7 Global Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2023-2034) ($MN)
  • Table 8 Global Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2023-2034) ($MN)
  • Table 9 Global Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2023-2034) ($MN)
  • Table 10 Global Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2023-2034) ($MN)
  • Table 11 Global Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2023-2034) ($MN)
  • Table 12 Global Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 13 Global Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 14 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 15 Global Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2023-2034) ($MN)
  • Table 16 Global Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2023-2034) ($MN)
  • Table 17 Global Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2023-2034) ($MN)
  • Table 18 Global Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 19 Global Prostate Cancer Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 20 Global Prostate Cancer Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 21 Global Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2023-2034) ($MN)
  • Table 22 Global Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 23 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 24 Global Prostate Cancer Diagnostics Market Outlook, By Home Care (2023-2034) ($MN)
  • Table 25 Global Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2023-2034) ($MN)
  • Table 26 Global Prostate Cancer Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 27 North America Prostate Cancer Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 28 North America Prostate Cancer Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 29 North America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2023-2034) ($MN)
  • Table 30 North America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2023-2034) ($MN)
  • Table 31 North America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2023-2034) ($MN)
  • Table 32 North America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2023-2034) ($MN)
  • Table 33 North America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2023-2034) ($MN)
  • Table 34 North America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2023-2034) ($MN)
  • Table 35 North America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2023-2034) ($MN)
  • Table 36 North America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2023-2034) ($MN)
  • Table 37 North America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2023-2034) ($MN)
  • Table 38 North America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 39 North America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 40 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 41 North America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2023-2034) ($MN)
  • Table 42 North America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2023-2034) ($MN)
  • Table 43 North America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2023-2034) ($MN)
  • Table 44 North America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 45 North America Prostate Cancer Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 46 North America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 47 North America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2023-2034) ($MN)
  • Table 48 North America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 49 North America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 50 North America Prostate Cancer Diagnostics Market Outlook, By Home Care (2023-2034) ($MN)
  • Table 51 North America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2023-2034) ($MN)
  • Table 52 North America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 53 Europe Prostate Cancer Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 54 Europe Prostate Cancer Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 55 Europe Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2023-2034) ($MN)
  • Table 56 Europe Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2023-2034) ($MN)
  • Table 57 Europe Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2023-2034) ($MN)
  • Table 58 Europe Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2023-2034) ($MN)
  • Table 59 Europe Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2023-2034) ($MN)
  • Table 60 Europe Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2023-2034) ($MN)
  • Table 61 Europe Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2023-2034) ($MN)
  • Table 62 Europe Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2023-2034) ($MN)
  • Table 63 Europe Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2023-2034) ($MN)
  • Table 64 Europe Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 65 Europe Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 66 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 67 Europe Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2023-2034) ($MN)
  • Table 68 Europe Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2023-2034) ($MN)
  • Table 69 Europe Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2023-2034) ($MN)
  • Table 70 Europe Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 71 Europe Prostate Cancer Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 72 Europe Prostate Cancer Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 73 Europe Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2023-2034) ($MN)
  • Table 74 Europe Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 75 Europe Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 76 Europe Prostate Cancer Diagnostics Market Outlook, By Home Care (2023-2034) ($MN)
  • Table 77 Europe Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2023-2034) ($MN)
  • Table 78 Europe Prostate Cancer Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 79 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 80 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 81 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2023-2034) ($MN)
  • Table 82 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2023-2034) ($MN)
  • Table 83 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2023-2034) ($MN)
  • Table 84 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2023-2034) ($MN)
  • Table 85 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2023-2034) ($MN)
  • Table 86 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2023-2034) ($MN)
  • Table 87 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2023-2034) ($MN)
  • Table 88 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2023-2034) ($MN)
  • Table 89 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2023-2034) ($MN)
  • Table 90 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 91 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 92 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 93 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2023-2034) ($MN)
  • Table 94 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2023-2034) ($MN)
  • Table 95 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2023-2034) ($MN)
  • Table 96 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 97 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 98 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 99 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2023-2034) ($MN)
  • Table 100 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 101 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 102 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Home Care (2023-2034) ($MN)
  • Table 103 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2023-2034) ($MN)
  • Table 104 Asia Pacific Prostate Cancer Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 105 South America Prostate Cancer Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 106 South America Prostate Cancer Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 107 South America Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2023-2034) ($MN)
  • Table 108 South America Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2023-2034) ($MN)
  • Table 109 South America Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2023-2034) ($MN)
  • Table 110 South America Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2023-2034) ($MN)
  • Table 111 South America Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2023-2034) ($MN)
  • Table 112 South America Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2023-2034) ($MN)
  • Table 113 South America Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2023-2034) ($MN)
  • Table 114 South America Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2023-2034) ($MN)
  • Table 115 South America Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2023-2034) ($MN)
  • Table 116 South America Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 117 South America Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 118 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 119 South America Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2023-2034) ($MN)
  • Table 120 South America Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2023-2034) ($MN)
  • Table 121 South America Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2023-2034) ($MN)
  • Table 122 South America Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 123 South America Prostate Cancer Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 124 South America Prostate Cancer Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 125 South America Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2023-2034) ($MN)
  • Table 126 South America Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 127 South America Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 128 South America Prostate Cancer Diagnostics Market Outlook, By Home Care (2023-2034) ($MN)
  • Table 129 South America Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2023-2034) ($MN)
  • Table 130 South America Prostate Cancer Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 131 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 132 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 133 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2023-2034) ($MN)
  • Table 134 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By PSA Tests (2023-2034) ($MN)
  • Table 135 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Free PSA Test (2023-2034) ($MN)
  • Table 136 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Total PSA Test (2023-2034) ($MN)
  • Table 137 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Preliminary Tests (2023-2034) ($MN)
  • Table 138 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2023-2034) ($MN)
  • Table 139 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Pca3 Test (2023-2034) ($MN)
  • Table 140 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2023-2034) ($MN)
  • Table 141 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Biopsy Test (2023-2034) ($MN)
  • Table 142 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2023-2034) ($MN)
  • Table 143 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 144 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 145 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Benign Prostatic Hyperplasia (2023-2034) ($MN)
  • Table 146 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2023-2034) ($MN)
  • Table 147 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2023-2034) ($MN)
  • Table 148 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other Cancer Types (2023-2034) ($MN)
  • Table 149 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 150 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 151 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Outpatient Facilities (2023-2034) ($MN)
  • Table 152 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 153 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 154 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Home Care (2023-2034) ($MN)
  • Table 155 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Research & Manufacturing (2023-2034) ($MN)
  • Table 156 Middle East & Africa Prostate Cancer Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)